It is known that melanoma tumors are minimally responsive to anti-angiogenesis agents6 and tumor vessels can rapidly regrow after the cessation of VEGF-targeted therapies,72,73,74 with VEGF inhibitors having proclivity for targeting vessels at the periphery of the tumor rather than those at the center.17 This evidence concerns the gene VEGFA and neoplasm.